Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous UrticariaAlan Brennan, S.T. Alexopoulos, Maria‐Magdalena Balp et al.|PharmacoEconomics|2016Cited by 40
EQ-5D Utilities in Chronic Spontaneous/Idiopathic UrticariaEmma Hawe, Donald E. Stull, Doreen McBride et al.|PharmacoEconomics|2016Cited by 18